Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Positive Metastatic Melanoma”

39 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 39 results

Not applicableStudy completedNCT01990248
What this trial is testing

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 339
Testing effectiveness (Phase 2)UnknownNCT04720768
What this trial is testing

Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

Who this might be right for
MelanomaMetastasis
Peter MacCallum Cancer Centre, Australia 78
Testing effectiveness (Phase 2)Study completedNCT01266967
What this trial is testing

GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

Who this might be right for
Melanoma and Brain Metastases
GlaxoSmithKline 172
Early research (Phase 1)Study completedNCT02027961
What this trial is testing

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Who this might be right for
Melanoma
MedImmune LLC 68
Testing effectiveness (Phase 2)UnknownNCT03514901
What this trial is testing

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Who this might be right for
Melanoma MetastaticBRAF V600 Mutation
Intergruppo Melanoma Italiano 120
Early research (Phase 1)Study completedNCT02608034
What this trial is testing

Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Genentech, Inc. 32
Post-approval studies (Phase 4)Study completedNCT01898585
What this trial is testing

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 60
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Testing effectiveness (Phase 2)Study completedNCT02392871
What this trial is testing

Radiotherapy & Combi in Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Melanoma and Skin Cancer Trials Limited 10
Early research (Phase 1)Looking for participantsNCT04913285
What this trial is testing

Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Who this might be right for
Solid Tumor, AdultNon-small Cell Lung CancerMelanoma
Pierre Fabre Medicament 400
Not applicableStudy completedNCT05611229
What this trial is testing

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Who this might be right for
Metastatic Melanoma
Novartis Pharmaceuticals 1,975
Large-scale testing (Phase 3)Active Not RecruitingNCT04657991
What this trial is testing

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Who this might be right for
Melanoma
Pfizer 257
Not applicableNo Longer AvailableNCT02416232
What this trial is testing

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline
Not applicableNo Longer AvailableNCT04489433
What this trial is testing

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals
Early research (Phase 1)WithdrawnNCT02145910
What this trial is testing

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

Who this might be right for
Recurrent MelanomaStage IV MelanomaTumors Metastatic to Brain
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Large-scale testing (Phase 3)Study completedNCT01597908
What this trial is testing

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 704
Testing effectiveness (Phase 2)Ended earlyNCT02410863
What this trial is testing

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

Who this might be right for
Malignant Melanoma
Prof. Dr. med. Dirk Schadendorf 10
Early research (Phase 1)Study completedNCT01264380
What this trial is testing

The Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 16
Testing effectiveness (Phase 2)Ended earlyNCT01978236
What this trial is testing

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Who this might be right for
Melanoma and Brain Metastases
GlaxoSmithKline 6
Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Next Page